- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02384369
Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder (PTSD)
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder Concomitantly Treated With Prazosin
This is a randomized, double-blind, placebo-controlled study of SNC-102 in adult subjects with cPTSD, added to pre-existing treatment that includes prazosin with or without other psychotropic drugs.
Subjects will be treated with SNC-102 tablets or matching placebo on a BID basis for 8 weeks. Subjects will be evaluated for the symptoms of combat-related posttraumatic stress disorder (cPTSD) as measured by the Clinician Administered PTSD Scale (CAPS-5), compared with the response to placebo.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmation of a diagnosis by a Board-Certified psychiatrist of combat-related posttraumatic stress disorder (cPTSD) according to Diagnostic and Statistical Manual (DSM-5) criteria for PTSD and a history linking the symptoms to combat exposure.
- Taking prazosin for treatment of cPTSD for a minimum of 4 weeks, on a stable dose for at least 2 weeks, and expected to remain on that dose for the duration of the study.
- Having sufficient residual symptoms of PTSD while on the current drug regimen that, in the opinion of the Principal Investigator, additional treatment of the disorder is clinically indicated.
- Body mass index of 18-38 kg/m2 inclusive.
Exclusion Criteria:
- Plans to initiate a new psychotropic medication (other than the study drug) during the period of the study.
- Plans to change the dose or discontinue prazosin or a psychotropic medication during the period of the study.
- Diagnosis of epilepsy or treatment with an antiepileptic drug.
- Use of alcohol or cannabis to the extent that, in the view of the Principal Investigator, it raises a significant risk of medication noncompliance, drinking alcohol after midnight on the days of study visits or missed study visits. Any use of non-prescribed opiates, cocaine, or other street drugs other than cannabis in the month prior to study entry.
- Any history of major medical complications of alcohol use including alcoholic hepatitis, cirrhosis of the liver, pancreatitis, alcohol withdrawal seizures, or delirium tremens.
- Patients taking moderate, stable doses of oral opiates for chronic pain may be admitted at the discretion of the Principal Investigator.
- Current use of a drug other than prazosin with significant alpha-adrenergic blocking effects, if associated with symptomatic orthostatic hypotension.
- Current use of cocaine, amphetamine, phencyclidine, or ketamine, documented either by history or by urinary drug screening at Screening and Baseline Visits. Urinary drug screening for ketamine and phencyclidine will conducted off-site by the Study Sponsor if urinary drug screening available at the study site does not include these drugs. Any other drugs identified incidentally on drug screening will warrant exclusion only if the Principal Investigator, in consultation with the Sponsor, judges that their presence could interfere with the objectives of the trial.
- Pregnant or lactating female.
- Women of childbearing potential, unless the subject agrees to use dual contraceptive methods while on study drug and for 1 month afterward, which, in the opinion of the Principal Investigator, are effective and adequate for that subject's circumstances.
- Any severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that could increase the risk associated with study participation or study drug administration, could interfere with the informed consent process and/or with compliance with the requirements of the study, or could interfere with the interpretation of study results and which, in the Principal Investigator's opinion, would make the subject inappropriate for entry into this study.
- Use of any non-pharmacologic psychiatric somatic treatment within 4 weeks of baseline, or expected during the course of the study. Such treatments include but are not limited to electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation, vagus nerve stimulation, light therapy, and acupuncture.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SNC-102 sustained release tablet
SNC-102 sustained release tablet for oral administration, 1600 mg BID for 8 weeks
|
Sustained release oral tablet of SNC-102
Other Names:
|
Placebo Comparator: Placebo
Placebo tablet for oral administration, BID for 8 weeks
|
Sustained release oral tablet of SNC-102
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PTSD symptoms as measured by Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual-5 (CAPS-5)
Time Frame: 8 weeks
|
Determine whether SNC-102 at a dose of 1600 mg twice daily (BID), added to pre-existing treatment that includes prazosin, will decrease the symptoms of combat-related posttraumatic stress disorder (cPTSD) as measured by the CAPS-5, compared with the response to placebo.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SNC-102-221 PT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Posttraumatic Stress Disorders
-
University of Missouri, Kansas CityUniversity of KansasUnknownPosttraumatic Stress DisordersUnited States
-
Hadassah Medical OrganizationUnknownPosttraumatic Stress DisordersIsrael
-
Kent State UniversityAkron Children's Hospital; Ohio Board of RegentsCompletedPosttraumatic Stress Disorders
-
University Hospital, ToursCompletedPostTraumatic Stress DisorderFrance
-
VA Office of Research and DevelopmentTerminatedPosttraumatic Stress DisordersUnited States
-
Canive, Jose M., M.D.Eli Lilly and CompanyUnknownPosttraumatic Stress DisordersUnited States
-
University of RochesterCompleted
-
University of New MexicoCompletedPostTraumatic Stress Disorder
-
Cambridge Health AllianceCompleted
-
The University of Texas Health Science Center at...University of Pennsylvania; Brooke Army Medical Center; C.R.Darnall Army Medical... and other collaboratorsCompletedPosttraumatic Stress Disorder (PTSD)United States
Clinical Trials on SNC-102 sustained release tablet
-
Synchroneuron Inc.WithdrawnTourette SyndromeUnited States
-
Luye Pharma Group Ltd.RecruitingTardive Dyskinesia | Huntington DiseaseChina
-
Luye Pharma Group Ltd.CompletedTardive Dyskinesia | Huntington DiseaseChina
-
Luye Pharma Group Ltd.RecruitingGeneralized Anxiety DisorderChina
-
Overseas Pharmaceuticals, Ltd.GX pharma technology (beijing) Co., LtdActive, not recruiting
-
Synchroneuron Inc.WithdrawnDrug-induced Tardive DyskinesiaUnited States
-
Meda PharmaceuticalsCompletedLower Back PainUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Shanghai Mental Health CenterNot yet recruiting
-
First Affiliated Hospital of Zhejiang UniversityHongguan biological pharmaceutical co.TerminatedParkinson's DiseaseChina